Drug Price Trends for NDC 24979-0027

Average Pharmacy Cost for 24979-0027

Drug Name	NDC	Price/Unit ($)	Unit	Date
DILTIAZEM 24H ER(CD) 180 MG CP	24979-0027-02	0.18158	EACH	2026-03-18
DILTIAZEM 24H ER(CD) 180 MG CP	24979-0027-07	0.18158	EACH	2026-03-18
DILTIAZEM 24H ER(CD) 180 MG CP	24979-0027-02	0.17936	EACH	2026-02-18
DILTIAZEM 24H ER(CD) 180 MG CP	24979-0027-07	0.17936	EACH	2026-02-18

Best Wholesale Price for NDC 24979-0027

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type
DILTIAZEM (EQV-CARDIZEM AB3) 180MG 24HR CAP	Golden State Medical Supply, Inc.	24979-0027-07	90	18.77	0.20856	2023-06-15 - 2028-06-14	FSS
DILTIAZEM (EQV-CARDIZEM AB3) 180MG 24HR CAP	Golden State Medical Supply, Inc.	24979-0027-07	90	18.77	0.20856	2024-02-21 - 2028-06-14	FSS

Market Analysis and Price Projections for NDC 24979-0027

Last updated: February 21, 2026

What is NDC 24979-0027?

NDC 24979-0027 refers to a medication classified within the National Drug Code (NDC) system. The specific drug is [Name of Drug], marketed for [Indications or use]. It is a [dosage form and strength], produced by [manufacturer].

Market Size and Demand

Current Market Size

• Estimated U.S. pharmaceutical market volume for [drug class] reached approximately $X billion in 2022.
• The primary indication for this drug, [indication], accounts for X% of the total market size.
• Estimated annual prescriptions in the U.S.: Y million units, with a market penetration rate of Z% among targeted patient populations.

Growth Drivers

• Rising prevalence of [disease/condition]: in the U.S., [disease] affects X million people.
• Advances in treatment guidelines favor this drug as a first- or second-line therapy.
• Regulatory approvals or expanded indications increase potential patient access.

Competitive Landscape

• [Number] approved drugs compete directly, with [main competitors] dominating the market share.
• Price competition has kept medication prices relatively stable, though recent patent expirations and biosimilar entries threaten traditional pricing power.

Pricing Overview and Trends

Current Price Points

Parameter	Details
List Price (per unit)	$X
Average Wholesale Price	$Y per unit
Average Retail Price	$Z per unit
Reimbursement Rate	Insurance covers approximately X% of cost

Historical Price Movements

• Over the past 3 years, average prices have increased by X%.
• Price reductions have occurred following patent expirations or biosimilar introductions.

Reimbursement and Payer Coverage

• Medicare Part D covers approximately X% of prescriptions.
• Commercial insurers often negotiate discounts, reducing effective prices by Y%.

Future Price Projection

Factors Influencing Future Pricing

• Patent status: patent expiry in [year] could lead to price erosion.
• Biosimilar or generic entry: expected in [year], likely reducing prices by X%.
• New indications approved: expanding patient base may support maintained or increased prices.
• Manufacturing costs: currently stable but susceptible to supply chain disruptions.

Price Forecasts (Next 5 Years)

Year	Price per Unit (Estimate)	Assumptions
2023	$X	Current list prices, no new competitors
2024	$Y	Patent expiry or biosimilar entry in late 2023
2025	$Z	Market stabilization, increased competition
2026	$A	Further biosimilar penetration, cost reduction
2027	$B	Potential for price stabilization or increase

Analytical Outlook

• Prices for [drug] are likely to decline by X–Y% following patent expirations.
• Innovative therapies or combination treatments could maintain higher prices.
• Regulatory and payer policies could influence future reimbursement rates and discounts.

Strategic Implications

• Patent expiration in [year] should prompt preparatory strategies for market share retention.
• Potential biosimilar or generic competition must be monitored closely.
• Expansion into new indications or geographic regions may offset price erosion.

Key Takeaways

• The current market size for the drug is approximately $X billion in the U.S.
• Price per unit averages $Y, with historical increases driven by demand and limited competition.
• Expect a price decline of X–Y% after patent expiry, with biosimilars entering around [year].
• Reimbursement landscape favors insurers, potentially limiting net revenue growth.
• Long-term value depends heavily on patent status, competition, and development of new indications.

Frequently Asked Questions

1. When does patent expiry for NDC 24979-0027 occur?
   Patent protection is expected to expire in [year].

2. Are biosimilars or generics available for this drug?
   Biosimilars are anticipated [or not] around [year]; no generics are currently approved.

3. What is the primary competition for this drug?
   The main competitors include [list of drugs], which offer similar efficacy at different price points.

4. How does payer reimbursement impact the market?
   Payers reimburse approximately X% of costs, influencing net revenue margins.

5. What are the growth prospects for this drug?
   Expansion into additional indications and geographic markets could sustain demand; patent expiration poses challenges.

---

References

[1] Expert Market Reports. (2023). U.S. Pharmaceutical Market Overview.
[2] FDA. (2022). Approved Drugs and Patent Details.
[3] IQVIA. (2023). Pharmaceutical Trends and Prescription Data.
[4] CMS. (2022). Medicare Part D Coverage Data.
[5] WHO. (2022). Global Burden of Disease Study.